Quench your thirst for knowledge.
We’re working with Pint of Science to bring ELRIG’s high-quality science to you!
Join Giles Yeo in Cambridge as he shares his discoveries and insights for his talk “Are the new class of GLP1 anti-obesity medications a panacea?“.
GLP1R agonists, including semaglutide (Ozempic) and tirzepatide (Mounjaro) are hugely effective in the treatment of obesity. Originally developed for Type 2 diabetes, these drugs also cause dramatic weight loss. But how do they work, and are these therapeutics the long sought after solution to obesity? Giles will explore the history of these drugs, explain its mechanisms of action, and discuss its importance as a therapeutic for obesity, type 2 diabetes, and heart disease, and crucially, whether or not it’s safe in the long term.
VENUE:
First Floor,
Grain & Hop,
69 Regent St, Cambridge
CB2 1AB
13 May | From 6:30pm
About Giles Yeo:
Giles Yeo got his PhD in molecular genetics from the University of Cambridge in 1998, after which he joined the lab of Prof Sir Stephen O’Rahilly, working on the genetics of severe human obesity. Giles Yeo is now a Professor of Molecular Neuroendocrinology and programme leader at the MRC Metabolic Diseases Unit in Cambridge and his research currently focuses on the influence of genes on feeding behaviour & body-weight. In addition, he is a fellow of Wolfson College, and Honorary President of the British Dietetic Association. Giles is also a broadcaster and author, presenting science documentaries for the BBC, and hosts a podcast called ‘Dr Giles Yeo Chews The Fat’. His first book ‘Gene Eating’ was published in December 2018, and his second book ‘Why Calories Don’t Count’ came out in June 2021. Giles was appointed an MBE in the Queen’s 2020 birthday honours for services to ‘Research, Communication and Engagement’. He won the Society for Endocrinology Medal in 2022.
